| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Acknowledgement to reviewers
|
|
|
|
151 |
C |
p. 112
|
artikel
|
| 2 |
ADVANCE-1: An adapted collaborative benchmarking approach in centre-based lung cancer care
|
McCann, Brendan
|
|
|
151 |
C |
p. 44-52
|
artikel
|
| 3 |
A novel HIP1-ALK fusion variant in lung adenocarcinoma showing resistance to Crizotinib
|
Li, Mengnan
|
|
|
151 |
C |
p. 98-100
|
artikel
|
| 4 |
A reply to “Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model”
|
Moldaver, Daniel
|
|
|
151 |
C |
p. 110-111
|
artikel
|
| 5 |
Clinical implications of germline BCL2L11 deletion polymorphism in pretreated advanced NSCLC patients with osimertinib therapy
|
Li, Xuanzong
|
|
|
151 |
C |
p. 39-43
|
artikel
|
| 6 |
Contents
|
|
|
|
151 |
C |
p. v-vi
|
artikel
|
| 7 |
Correspondence Re: Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model
|
Goffin, John R.
|
|
|
151 |
C |
p. 108-109
|
artikel
|
| 8 |
Detection of circulating tumor DNA by digital droplet PCR in resectable lung cancer as a predictive tool for recurrence
|
Gassa, Asmae
|
|
|
151 |
C |
p. 91-96
|
artikel
|
| 9 |
Disease flare of leptomeningeal metastases without radiological and cytological findings after the discontinuation of osimertinib
|
Takahashi, Toshiaki
|
|
|
151 |
C |
p. 1-4
|
artikel
|
| 10 |
Editorial Board
|
|
|
|
151 |
C |
p. iii
|
artikel
|
| 11 |
Efficacy of pembrolizumab in patients with brain metastasis caused by previously untreated non-small cell lung cancer with high tumor PD-L1 expression
|
Wakuda, Kazushige
|
|
|
151 |
C |
p. 60-68
|
artikel
|
| 12 |
Erlotinib plus bevacizumab vs erlotinib monotherapy as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer: Survival follow-up results of the randomized JO25567 study
|
Yamamoto, N.
|
|
|
151 |
C |
p. 20-24
|
artikel
|
| 13 |
Evaluation of NTRK immunohistochemistry as a screening method for NTRK gene fusion detection in non-small cell lung cancer
|
Elfving, Hedvig
|
|
|
151 |
C |
p. 53-59
|
artikel
|
| 14 |
GPC1-ALK: A novel ALK fusion in a patient with pulmonary sarcomatoid carcinoma
|
Xiong, Lei
|
|
|
151 |
C |
p. 104-105
|
artikel
|
| 15 |
HER2 amplification as a potential mechanism of acquired resistance to afatinib in an advanced non-small-cell lung cancer patient
|
Wang, Mingwei
|
|
|
151 |
C |
p. 106-107
|
artikel
|
| 16 |
Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC)
|
Faivre-Finn, Corinne
|
|
|
151 |
C |
p. 30-38
|
artikel
|
| 17 |
Letter: Exploring the accuracy of biopsy in diagnosis of pulmonary sarcomatoid carcinoma
|
Yang, Zhen-Yu
|
|
|
151 |
C |
p. 97
|
artikel
|
| 18 |
New N1/N2 classification and lobe specific lymphatic drainage: Impact on survival in patients with non-small cell lung cancer treated with surgery
|
Tsitsias, Thomas
|
|
|
151 |
C |
p. 84-90
|
artikel
|
| 19 |
PDL1 high expression without TP53, KEAP1 and EPHA5 mutations could better predict survival for patients with NSCLC receiving atezolizumab
|
Wang, Haiyong
|
|
|
151 |
C |
p. 76-83
|
artikel
|
| 20 |
Pemetrexed maintenance with or without pembrolizumab in non-squamous non-small cell lung cancer: A cross-trial comparison of KEYNOTE-189 versus PARAMOUNT, PRONOUNCE, and JVBL
|
Garon, Edward B.
|
|
|
151 |
C |
p. 25-29
|
artikel
|
| 21 |
PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project
|
Blons, H.
|
|
|
151 |
C |
p. 69-75
|
artikel
|
| 22 |
Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer
|
Lee, Youngjoo
|
|
|
151 |
C |
p. 8-15
|
artikel
|
| 23 |
RB1 loss induced small cell lung cancer transformation as acquired resistance to pembrolizumab in an advanced NSCLC patient
|
Arakawa, Sayaka
|
|
|
151 |
C |
p. 101-103
|
artikel
|
| 24 |
Risk of second primary malignancies among patients with carcinoid of the lung
|
Buikhuisen, Wieneke A.
|
|
|
151 |
C |
p. 5-7
|
artikel
|
| 25 |
Thyroid dysfunction in non-small cell lung cancer patients treated with epidermal growth factor receptor and anaplastic lymphoma kinase inhibitors: Results of a prospective cohort
|
Soni, Swati
|
|
|
151 |
C |
p. 16-19
|
artikel
|
Tijdschrift beschrijving